The STOPBAG2 scoring instrument, which incorporates sleep-related symptoms and continuous variables for age and BMI, offers greater discriminatory power for predicting all levels of OSA severity in adults with epilepsy.
Researchers find that many Huntington disease specialist clinics do not have the resources available to administer DMTs appropriately with an intrathecal strategy.
Certain components of metabolic syndrome may be more common in patients with Parkinson disease who are carriers of an LRRK2 mutation compared with other PD etiologies.
Prolonged delays from ICH symptom onset to hospital presentation is associated with worse functional outcomes at 3 months, compared with earlier presentation.
Treatment with fremanezumab for episodic and chronic migraine was found to have a favorable cardiovascular safety profile in patients with and without a history of cardiovascular disease.
Pimavanserin, either alone or in conjunction with a selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor, may improve comorbid depression symptoms in patients with Parkinson disease.
Individuals with vs without status epilepticus were found to have a greater prevalence of cardiovascular risk factors and a higher risk of developing cardiovascular diseases.
Switching from natalizumab to moderate DMT vs switching to high efficacy therapy in MS patients was associated with lower rates of no disease activity.
